<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129736</url>
  </required_header>
  <id_info>
    <org_study_id>TERIFL0519</org_study_id>
    <secondary_id>2016-004414-10</secondary_id>
    <nct_id>NCT04129736</nct_id>
  </id_info>
  <brief_title>Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis</brief_title>
  <official_title>Determination of Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis Treated With Teriflunomide 14 mg Daily.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jan Lycke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Serum and cerebrospinal fluid will be obtained from 20 patients with relapsing-remitting
      multiple sclerosis treated with teriflunomide tablets 14 mg daily
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Teriflunomide concentration in cerebrospinal fluid and serum will be determined in 20
      patients with multiple sclerosis. They have been treated for at least 6 months and the
      sampling from blood and by spinal tap is done before dose at 8 am in 10 patients and at 12 am
      in 10 patients. The dependence from age, sex, and blood-brain barrier (BBB) integrity will be
      evaluated.The ratio between serum and cerebrospinal fluid will determine the passage over the
      BBB.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pharmacokinetic</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of teriflunomide in cerebrospinal fluid</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Sclerosis, Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Teriflunomide 14 mg tablets</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriflunomide 14 MG</intervention_name>
    <description>Blood and cerebrospinal fluid is obtained from teriflunomide treated patients with multiple sclerosis</description>
    <arm_group_label>Teriflunomide 14 mg tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with multiple sclerosis treated with teriflunomide 14 mg for at least 6
             months

        Exclusion Criteria:

          -  other immunosuppressive or immunomodulating drugs, other CNS diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jan Lycke, PI</last_name>
    <phone>+46733109149</phone>
    <email>jan.lycke@neuro.gu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Frandsen Brandt, Study nurse</last_name>
    <phone>+46703406085</phone>
    <email>anne.frandsen.brandt@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MS Centre</name>
      <address>
        <city>Gothenburg</city>
        <state>Vastra Gotaland</state>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Lycke, PI</last_name>
      <phone>+46733109149</phone>
      <email>jan.lycke@neuro.gu.se</email>
    </contact>
    <contact_backup>
      <last_name>Anne Frandsen Brandt, Study Nurse</last_name>
      <phone>+46703406085</phone>
      <email>anne.frandsen.brandt@vgregion.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2019</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Jan Lycke</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No additional plan will be added</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

